Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (19,698)	$ (567)
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of deferred financing costs	1,284	1,768
Depreciation, amortization and accretion	36,310	27,597
Stock-based compensation expense	1,818	1,972
Change in fair value of interest rate swaps	1,814	4,638
Loss on disposal of property	885	0
Loss (gain) on the extinguishment of debt	6,767	(5,735)
Unrealized gains on foreign currency, net	(29,823)	(21,239)
Deferred tax benefit	(557)	(511)
Other non-cash items	(2,348)	0
Changes in assets and liabilities:
Accounts receivable	1,324	3,366
Prepaid expenses and other current assets	(15,094)	7,037
Accounts payable, accrued expenses, and other current liabilities	10,224	(11,544)
Due to/from affiliates, net	(6,338)	(3,192)
Net cash (used in) provided by operating activities	(13,432)	3,590
Cash flows from investing activities:
Capital expenditures	(3,486)	(47,105)
Change in restricted cash	2,778	57,103
Cash paid for acquisitions, net of cash acquired	0	(32,128)
Cash acquired upon FERSA consolidation	0	8,022
Returns from BioTherm escrow and deposits	2,430	3,775
Net cash provided by (used in) investing activities	1,722	(10,333)
Cash flows from financing activities:
Repayments of the Senior Notes	0	(35,441)
Repayments of system debt financing	(7,906)	(29,477)
Net SunEdison investment	0	48,983
Dividends paid	0	(30,674)
Net cash used in financing activities	(7,906)	(46,609)
Net decrease in cash and cash equivalents	(19,616)	(53,352)
Effect of exchange rate changes on cash and cash equivalents	(11,036)	1,528
Cash and cash equivalents at beginning of period	680,893	922,318
Cash and cash equivalents at end of period	$ 650,241	$ 870,494